Research progress of the relationship between subclinical hyperthyroidism and cardiovascular disease
-
摘要: 亚临床甲状腺功能亢进症是指促甲状腺激素低于正常范围,而甲状腺激素在正常范围的一类疾病。亚临床甲亢被认为是处于健康及临床甲亢的中间状态,是否可导致心血管事件的发生风险增加,以及是否需要筛查及积极干预治疗,既往相关研究结果,结论不一;近来研究表明亚临床甲状腺亢进症与心血管疾病的发生、发展与不利转归密切相关,本文就亚临床甲状腺功能亢进症与心血管疾病关系的研究进展作一综述。
-
关键词:
- 亚临床甲状腺功能亢进症 /
- 心血管危险因素 /
- 心血管疾病 /
- 心血管死亡
Abstract: Subclinical hyperthyroidism was defined as a serum thyrotropin (TSH) concen-tration below the nomal range with normal levels of thyroid hormones, which was considered to be an intermediate state between health and clinical hyperthyroidism.Whether subclinical hyperthyroidism increased the risk of cardiovascular disease and should be screened and actively treated, results of the previous relevant researches remain controversial. Recent studies showed that subclinical hyperthyroidism was significantly associated with higher risk of cardiovascular disease and cardiovascular mor-tality. We reviewed the research development of the relationship between subclinical hyperthyroidism and cardiovascular disease. -
[1] Klein I, Danzi S. Thyroid disease and the heart[J]. Circulation, 2007, 116(15): 1725-35. doi: 10.1161/CIRCULATIONAHA.106.678326 [2] Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES Ⅲ)[J]. J Clin Endocrinol Metab, 2002, 87(2): 489-99. doi: 10.1210/jcem.87.2.8182 [3] Cappola AR, Fried LP, Arndd AM, et al. Thyroid status, Cardio-Vascular risk, and mortality in older adults: the cardiovascular HealthStudy[J]. JAMA, 2006, 295(9): 1033-41. doi: 10.1001/jama.295.9.1033 [4] Laurberg P, Cerqueira C, Ovesen L, et al. Iodine intake as a determinant of thyroid disorders in populations[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(1): 13-27. doi: 10.1016/j.beem.2009.08.013 [5] Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over[J]. J Clin Endocrinol Metab, 2009, 94(4): 1342-5. doi: 10.1210/jc.2008-1696 [6] Cooper DS, Biondi B. Subclinical thyroid disease[J]. Lancet, 2012, 379(9821): 1142-54. doi: 10.1016/S0140-6736(11)60276-6 [7] Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid thera-py for Endogenous subclinical hyperthyroidism in clinical and heart abnormal-lities[J]. J Clin Endocrinol Metab, 2003, 88(4): 1672-7. doi: 10.1210/jc.2002-021046 [8] Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of Life and cardiac morphology and function in young and middle-aged patients[J]. J Clin Endocrinol Metab, 2000, 85(12): 4701-5. http://www.ncbi.nlm.nih.gov/pubmed/11134131 [9] Maratou E, Hadjidakis DJ, Peppa MA, et al. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism [J]. Eur J Endocrinol, 2010, 163(4): 625-30. https://www.ncbi.nlm.nih.gov/pubmed/19141606 [10] Yavuz DG, Yüksel M, Deyneli O, et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients[J]. Clin Endocrinol (Oxf), 2004, 61(4): 515-21. doi: 10.1111/cen.2004.61.issue-4 [11] Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects [J]. J Clin Endocrinol Metab, 2007, 92(2): 491-6. doi: 10.1210/jc.2006-1718 [12] Yang LB, Jiang DQ, Qi WB, et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies[J]. Eur J Endocrinol, 2012, 167(1): 75-84. doi: 10.1530/EJE-12-0015 [13] Klein I, Ojamaa K. Thyroid hormone and the cardiovascuclar system [J]. N Engl J Med, 2001, 344(7): 501-9. doi: 10.1056/NEJM200102153440707 [14] Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts[J]. Circulation, 2012, 126(9): 1040-9. doi: 10.1161/CIRCULATIONAHA.112.096024 [15] Pearce EN, Yang Q, Benjamin EJ, et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study [J]. Thyroid, 2010, 20(4): 369-73. doi: 10.1089/thy.2009.0272 [16] Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study[J]. J Clin Endocrinol Metab, 2014, 99(7): 2372-82. doi: 10.1210/jc.2013-4184 [17] Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study[J]. BMJ, 2012, 345(7): e7895-9. https://www.ncbi.nlm.nih.gov/pubmed/23186910 [18] Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly People from one low serum thyrotropin result: a 10-year cohort study[J]. Lancet, 2001, 358(9285): 861-5. doi: 10.1016/S0140-6736(01)06067-6 [19] Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality[J]. Arch Intern Med, 2012, 172(10): 799-809. https://www.ncbi.nlm.nih.gov/pubmed/22529182 [20] Kita PA, Siewko K, Telejko B, et al. The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overthyperthyroidism[J]. Int J Endocrinol, 2013, 13(5): 981638-45. https://www.ncbi.nlm.nih.gov/pubmed/24367378 [21] Erem C, Civan N, Coskun H, et al. Signal peptide-CUB-EGF domain-containing protein 1(SCUBE1)levels in patients with overt and subclinical hyperthyroidism:effects of treatment[J]. Clin Endocrinol(Oxf), 2015, 16(9): 458-63. http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fcen.12955 [22] Coban E, Aydemir M, Yazicioglu G, et al. Endothelial dysfunction in subjects with subclinical hyperthyroidism[J]. J Endocrinol Invest, 2006, 29(3): 197-200. doi: 10.1007/BF03345539 [23] Coban E, Aydemir M. Levels of plasma fibrinogen and D-dimer in subjects with subclinical hyperthyroidism[J]. Med Sci Monit, 2008, 14(1): CR42-6. https://www.ncbi.nlm.nih.gov/pubmed/18160944 [24] Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma[J]. Clin Endocrinol (Oxf), 2010, 73(4): 502-7. https://www.ncbi.nlm.nih.gov/pubmed/20039901 [25] Singh S, Duggal J, Molnar J, et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis[J]. Int J Cardiol, 2008, 125(1): 41-8. doi: 10.1016/j.ijcard.2007.02.027 [26] Vadiveloo T, Donnan PT, Cochrane L, et al. The thyroid epidemiology, audit, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism[J]. J Clin Endocrinol Metab, 2011, 96(5): 1344-51. doi: 10.1210/jc.2010-2693 [27] Faber J, Wiinberg N, Schifter S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism[J]. Eur J Endocrinol, 2001, 145(4): 391-6. doi: 10.1530/eje.0.1450391 [28] Kaminski G, Michalkiewicz D, Makowski K, et al. Prospective echo-cardiographic evaluation of patients with endogenous subclinicalhyperthyroidism and after restoring euthyroidism[J]. Clin Endocrinol (Oxf), 2011, 74(4): 501-7. doi: 10.1111/cen.2011.74.issue-4 [29] Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities[J]. J Clin Endocrinol Metab, 2003, 88(4): 1672-7. doi: 10.1210/jc.2002-021046
点击查看大图
计量
- 文章访问数: 1083
- HTML全文浏览量: 341
- PDF下载量: 2
- 被引次数: 0